THERAPY DOSSIER · th-b4b3630455d1

Cyclotraxin B (BDNF-TrkB receptor antagonist); comparators pregabalin, ketamine, morphine, tapentadol and agomelatine

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Crush
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26343858 ↗2015Reported benefit

Respective pharmacological features of neuropathic-like pain evoked by intrathecal BDNF versus sciatic nerve ligation in rats.

RatCrushPeripheral-nerve crushSprague-DawleymaleAcute systemic administration for cyclotraxin B; intrathecal for BDNF (3.0 ng)Acute treatment after establishment of hyperalgesia in chronic constriction inj…

Model: Unilateral chronic constriction injury to the sciatic nerve (CCI-SN); comparator model of intrathecal BDNF injection (3.0 ng) in intact healthy rats

Acute cyclotraxin B completely prevented intrathecal BDNF-induced hyperalgesia and partially reversed hyperalgesia in both BDNF-pretreated and chronic constriction injury rats. Pregabalin, ketamine, morphine, tapentadol and agomelatine each transiently reversed hyperalgesia in both models. Chronic…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…